Background Following severe limb ischemia requiring urgent/emergent revascularization,
peripheral arterial disease patients suffer a high risk of recurrent atherothrombosis. Methods …

Patients with peripheral artery disease who undergo urgent or emergent lower extremity
revascularization have the highest risk of major adverse cardiac and limb events. Although …

Objectives Acute limb ischemia (ALI) is a major adverse limb event associated with high
morbidity and mortality. Despite the severity of this outcome, there are few large datasets …

Background: Acute limb ischemia (ALI) is an important clinical event and an emerging
cardiovascular clinical trial outcome. Risk factors for and outcomes after ALI have not been …

Background Premature peripheral artery disease (PAD), defined by lower extremity
revascularization (LER) at age≤ 50 years, is associated with poor major adverse limb …

Cardioprotective medications and risk-factor modification are the hallmarks of treatment for
all patients with peripheral artery disease (PAD). If symptoms are life-limiting and/or do not …

Abstract Background The VOYAGER PAD trial demonstrated the superiority of aspirin (ASA)
and low dose rivaroxaban (COMPASS trial dosing) compared with ASA alone in reducing …

Objectives Antiplatelet therapy following peripheral arterial endovascular intervention lacks
high quality evidence to guide practice. The aim of this study was to assess the effect of …

Given the very ill nature of patients with critical limb ischemia (CLI), the use of percutaneous
vascular interventions (PVIs) for limb salvage may or may not be efficacious; in particular, for …

Objective Optimizing medical management and risk factor modification are underused
strategies in patients with chronic limb-threatening ischemia (CLTI), despite evidence of …